Patents by Inventor Gerhard Frey

Gerhard Frey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10954288
    Abstract: The present invention relates to modified Fc regions of antibodies, and uses thereof, such as in antibodies that contain an Fc region of the present invention.
    Type: Grant
    Filed: March 2, 2018
    Date of Patent: March 23, 2021
    Assignee: BioAtla, Inc.
    Inventors: Gerhard Frey, Jay M. Short, Hwai Wen Chang
  • Publication number: 20210077222
    Abstract: A labelling system includes a labelling plate being adapted to be removably connected with a sterile container, wherein the labelling plate includes interfaces for at least one label (e.g. barcode) and at least one identification tag (e.g. RFID). The interfaces can removably hold the at least one identification tag and/or the at least one label at the separate labelling plate.
    Type: Application
    Filed: December 14, 2017
    Publication date: March 18, 2021
    Inventors: Elmar HEID, Gerhard FREY, Frank WELLER, Tommy SCHUBERT, Edward NUBER
  • Publication number: 20200407439
    Abstract: A non-naturally occurring polypeptide or isolated polypeptide having a ratio of at least 1.3 of an activity in an assay at a first pH in the presence of at least one species having a molecular weight of less than 900 a.m.u. and a pKa up to 4 pH units away from said first pH, to an activity in an assay at a second pH in the presence of the same at least one species. The species has a pKa between said first pH and said second pH and can be a small molecule. Also disclosed are pharmaceutical formulations including the polypeptide and uses thereof. Methods of producing conditionally active polypeptides are also disclosed.
    Type: Application
    Filed: August 31, 2016
    Publication date: December 31, 2020
    Applicant: BioAtla, LLC
    Inventors: Jay M. SHORT, Hwai Wen CHANG, Gerhard FREY
  • Publication number: 20200298791
    Abstract: The invention relates to a belt deflector with a main element (100) that can be attached to the structure of a vehicle, and with a belt support element (200) that is movable relative to the main element (100) and forms a support surface (231) or support edge for a safety belt (20) to be deflected. According to the invention, the belt deflector comprises an intermediate element (300, 400) that is deformed when the movable belt support element (200) is moved relative to the main element (100), in the direction of the intermediate element (300, 400), and because of this deformation is pressed against the safety belt (20).
    Type: Application
    Filed: March 9, 2017
    Publication date: September 24, 2020
    Applicant: Joyson Safety Systems Germany GmbH
    Inventors: Yves CLAUSS, Heinrich EINSIEDEL, Gerhard FREY, Peter LINDE, Rainer MANGOLD, Thomas BERTRAM
  • Patent number: 10696750
    Abstract: The present invention is relevant to the generation of multi-specific antibodies, antibodies that are distinguished by their ability to bind to multiple antigens with specificity and with affinity. In particular, the present invention is related to bi-specific antibodies.
    Type: Grant
    Filed: January 31, 2019
    Date of Patent: June 30, 2020
    Assignee: BioAtla, LLC
    Inventors: Gerhard Frey, Hwai Wen Chang, Jay M. Short
  • Publication number: 20200199578
    Abstract: Methods of generating conditionally active biologic proteins, in particular therapeutic or diagnostic proteins, which are more active at an aberrant condition than at a normal physiological condition. The methods include discovery methods using libraries of proteins and assays employing physiological concentrations of components of bodily fluids. The conditionally active biologic proteins may be further evolved, conjugated to other molecules, masked, reduced in activity by attaching a cleavable moiety. Criteria for selecting starting proteins for the discovery methods, as well as formats of the proteins are also disclosed.
    Type: Application
    Filed: January 3, 2020
    Publication date: June 25, 2020
    Applicant: BIOATLA, LLC
    Inventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
  • Publication number: 20200190503
    Abstract: A method of preparing a conditionally active polypeptide from a parent polypeptide, comprising steps of evolving a DNA encoding the parent polypeptide by increasing a net charge of the parent polypeptide using one or more techniques selected from increasing a total number of codons of charged amino acid residues in the DNA and decreasing a total number of codons of uncharged amino acid residues in the DNA to create mutant DNAs; expressing the mutant DNAs to obtain mutant polypeptides; and selecting the conditionally active polypeptide from the mutant polypeptides which exhibits a decrease in activity in a first assay at a first value of a condition compared to the same activity in a second assay at a second value of the same condition. The conditionally active polypeptide, pharmaceutical compositions containing same, nanoparticle and drug conjugates thereof and uses thereof are also provided.
    Type: Application
    Filed: August 22, 2017
    Publication date: June 18, 2020
    Applicant: BioAtla, LLC
    Inventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
  • Patent number: 10676524
    Abstract: Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to CD47 of multiple mammalian species, block the binding of SIRPalpha and TSP1 to CD47, promote phagocytosis of susceptible cancer cells, and reverse TSP1 inhibition of nitric oxide signaling, as well as monoclonal antibodies and antigen binding fragments thereof that compete with the former for binding to CD47 and that exhibit similar biological activities. Also provided are combinations of any of the foregoing. Such antibody compounds are variously effective in 1) treating tissue ischemia and ischemia-reperfusion injury (IRI) in the setting of organ preservation and transplantation, pulmonary hypertension, sickle cell disease, myocardial infarction, stroke, and other instances of surgery and/or trauma in which IRI is a component of pathogenesis; 2) in treating autoimmune and inflammatory diseases; and 3) as anti-cancer agents for treating susceptible cancer cells, promoting their phagocytic uptake and clearance.
    Type: Grant
    Filed: October 3, 2017
    Date of Patent: June 9, 2020
    Assignee: Arch Oncology, Inc.
    Inventors: William A. Frazier, Pamela T. Manning, Gerhard Frey, Hwai Wen Chang
  • Patent number: 10669336
    Abstract: Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to CD47 of multiple mammalian species, block the binding of SIRPalpha and TSP1 to CD47, promote phagocytosis of susceptible cancer cells, and reverse TSP1 inhibition of nitric oxide signaling, as well as monoclonal antibodies and antigen binding fragments thereof that compete with the former for binding to CD47 and that exhibit similar biological activities. Also provided are combinations of any of the foregoing. Such antibody compounds are variously effective in 1) treating tissue ischemia and ischemia-reperfusion injury (IRI) in the setting of organ preservation and transplantation, pulmonary hypertension, sickle cell disease, myocardial infarction, stroke, and other instances of surgery and/or trauma in which IRI is a component of pathogenesis; 2) in treating autoimmune and inflammatory diseases; and 3) as anti-cancer agents for treating susceptible cancer cells, promoting their phagocytic uptake and clearance.
    Type: Grant
    Filed: October 3, 2017
    Date of Patent: June 2, 2020
    Assignee: Arch Oncology, Inc.
    Inventors: William A. Frazier, Pamela T. Manning, Gerhard Frey, Hwai Wen Chang
  • Publication number: 20200085070
    Abstract: In one aspect, the invention is directed to polypeptides having an amylase activity, polynucleotides encoding the polypeptides, and methods for making and using these polynucleotides and polypeptides. In one aspect, the polypeptides of the invention can be used as amylases, for example, alpha amylases, to catalyze the hydrolysis of starch into sugars. In one aspect, the invention provides delayed release compositions comprising a desired ingredient coated by a latex polymer coating.
    Type: Application
    Filed: February 15, 2019
    Publication date: March 19, 2020
    Inventors: Walter CALLEN, Toby RICHARDSON, Gerhard FREY, Kevin A. GRAY, Janne S. KEROVUO, Malgorzata SLUPSKA, Nelson R. BARTON, Eileen O'DONOGHUE, Carl MILLER
  • Patent number: 10563194
    Abstract: Methods of generating conditionally active biologic proteins, in particular therapeutic or diagnostic proteins, which are more active at an aberrant condition than at a normal physiological condition. The methods include discovery methods using libraries of proteins and assays employing physiological concentrations of components of bodily fluids. The conditionally active biologic proteins may be further evolved, conjugated to other molecules, masked, reduced in activity by attaching a cleavable moiety. Criteria for selecting starting proteins for the discovery methods, as well as formats of the proteins are also disclosed.
    Type: Grant
    Filed: February 24, 2016
    Date of Patent: February 18, 2020
    Assignee: BioAlta, LLC
    Inventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
  • Publication number: 20200002414
    Abstract: A polypeptide having a heavy chain variable region and/or light chain variable region that specifically binds to Ror2 protein as well as antibodies and antibody fragments containing the heavy chain variable region and/or the light chain variable region that bind to Ror2 protein.
    Type: Application
    Filed: May 12, 2017
    Publication date: January 2, 2020
    Applicant: BioAtla, LLC
    Inventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
  • Publication number: 20190284551
    Abstract: This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at some physiological conditions. For example, conditionally active biologic proteins are active in tumors, but virtually inactive at other body parts, or conditionally active antibodies capable of crossing blood-brain-barrier.
    Type: Application
    Filed: May 28, 2019
    Publication date: September 19, 2019
    Applicant: BioAtla, LLC
    Inventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
  • Publication number: 20190248892
    Abstract: Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to, and inhibit the activity of, CD47, as well as monoclonal antibodies and antigen binding fragments thereof that compete with the former for binding to CD47. Also provided are combinations of any of the foregoing. Such antibody compounds are variously effective in 1) treating tissue ischemia and ischemic-reperfusion injury (IRI) in the setting of organ preservation and transplantation, pulmonary hypertension, sickle cell disease, myocardial infarction, stroke, and other instances of surgery and/or trauma in which IRI is a component of pathogenesis; 2) in treating autoimmune and inflammatory diseases; and 3) as anti-cancer agents that are toxic to susceptible cancer cells, promoting their phagocytic uptake and clearance, or directly killing such cells.
    Type: Application
    Filed: February 28, 2019
    Publication date: August 15, 2019
    Inventors: William A. Frazier, Pamela T. Manning, Gerhard Frey, Hwai Wen Chang
  • Patent number: 10329556
    Abstract: This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at some physiological conditions. For example, conditionally active biologic proteins are active in tumors, but virtually inactive at other body parts, or conditionally active antibodies cap able of crossing blood-brain-barrier.
    Type: Grant
    Filed: May 11, 2015
    Date of Patent: June 25, 2019
    Assignee: BioAtla, LLC
    Inventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
  • Publication number: 20190177417
    Abstract: A polypeptide having a heavy chain variable region and/or light chain variable region that specifically binds to Axl protein as well as antibodies and antibody fragments containing the heavy chain variable region and/or the light chain variable region that bind to Axl protein. Pharmaceutical compositions and kits comprising the polypeptide or antibodies and antibody fragments containing the polypeptide are also provided.
    Type: Application
    Filed: April 13, 2017
    Publication date: June 13, 2019
    Applicant: BioAtla, LLC
    Inventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey
  • Publication number: 20190153120
    Abstract: The present invention is relevant to the generation of multi-specific antibodies, antibodies that are distinguished by their ability to bind to multiple antigens with specificity and with affinity. In particular, the present invention is related to bi-specific antibodies.
    Type: Application
    Filed: January 31, 2019
    Publication date: May 23, 2019
    Applicant: BioAtla, LLC
    Inventors: Gerhard Frey, Hwai Wen Chang, Jay M. Short
  • Patent number: 10259873
    Abstract: Provided are monoclonal antibodies and antigen-binding fragments thereof that bind to, and inhibit the activity of, CD47, as well as monoclonal antibodies and antigen binding fragments thereof that compete with the former for binding to CD47. Also provided are combinations of any of the foregoing. Such antibody compounds are variously effective in 1) treating tissue ischemia and ischemia-reperfusion injury (IRI) in the setting of organ preservation and transplantation, pulmonary hypertension, sickle cell disease, myocardial infarction, stroke, and other instances of surgery and/or trauma in which IRI is a component of pathogenesis; 2) in treating autoimmune and inflammatory diseases; and 3) as anti-cancer agents that are toxic to susceptible cancer cells, promoting their phagocytic uptake and clearance, or directly killing such cells.
    Type: Grant
    Filed: November 8, 2016
    Date of Patent: April 16, 2019
    Assignee: Arch Oncology, Inc.
    Inventors: William A. Frazier, Pamela T. Manning, Gerhard Frey, Hwai Wen Chang
  • Patent number: 10196617
    Abstract: This invention relates to phytases, polynucleotides encoding them, uses of the polynucleotides and polypeptides of the invention, as well as the production and isolation of such polynucleotides and polypeptides. In particular, the invention provides polypeptides having phytase activity under high temperature conditions, and phytases that retain activity after exposure to high temperatures. The phytases of the invention can be thermotolerant and/or thermostable at low temperatures, in addition to higher temperatures. The phytases of the invention can be used in foodstuffs to improve the feeding value of phytate rich ingredients. The phytases of the invention can be formulated as foods or feeds or supplements for either to, e.g., aid in the digestion of phytate. The foods or feeds of the invention can be in the form of pellets, liquids, powders and the like.
    Type: Grant
    Filed: October 2, 2014
    Date of Patent: February 5, 2019
    Assignee: BASF Enzymes LLC
    Inventors: Arne Solbak, Brian Steer, Mark Dycaico, Katie A. Kline, Axel Trefzer, Thomas Todaro, Fatima El-Farrah, Alberto Alvarado, Gerhard Frey
  • Publication number: 20190024078
    Abstract: Methods of generating conditionally active biologic proteins, in particular therapeutic or diagnostic proteins, which are more active at an aberrant condition than at a normal physiological condition. The methods include discovery methods using libraries of proteins and assays employing physiological concentrations of components of bodily fluids. The conditionally active biologic proteins may be further evolved, conjugated to other molecules, masked, reduced in activity by attaching a cleavable moiety. Criteria for selecting starting proteins for the discovery methods, as well as formats of the proteins are also disclosed.
    Type: Application
    Filed: February 24, 2016
    Publication date: January 24, 2019
    Applicant: BIOATLA, LLC
    Inventors: Jay M. Short, Hwai Wen Chang, Gerhard Frey